12 research outputs found
Közös felelősség a gyulladásos bélbetegség diagnosztikájában és kezelésében. Mikor utaljuk a gyulladásos bélbetegséggel kezelt beteget biológiai terápiás centrumba? = Shared responsibility in the diagnosis and treatment of inflammatory bowel disease : When to refer a patient with inflammatory bowel disease to a biological therapy center?
Összefoglaló. Az idült betegségek, köztük a gyulladásos bélbetegség kezelése összetett feladat, amely a megfelelő technikai feltételek mellett naprakész szaktudással és tapasztalattal rendelkező egészségügyi személyzet együttműködését igényli. Célunk a gyulladásos bélbetegség ellátásának célirányos összegzése volt. Kiemelten foglalkoztunk a korai diagnosztika és szakorvoshoz utalás kérdésével, a korszerű ellátáshoz szükséges, személyre szabott terápia és a célértékre történő kezelés, valamint a biológiai terápiás centrumba utalás szükségességével. Részleteztük továbbá a kompetens és felelősségteljes gondozás ellátószintjeit, és bemutattuk az ellátásban együttműködő multidiszciplináris csoport felépítését is. Az összefoglaló közleményhez a nemzetközi irodalmat és a hazai terápiás protokollokat tekintettük át. A krónikus betegségek gondozásában elengedhetetlen a társszakmák együttműködése. A betegség kezelésében fontos a folyamatosan változó ajánlások, protokollok ismerete és a kompetenciaszintek elfogadása a beteg megfelelő életminőségének elérése és a szövődmények csökkentése céljából. Orv Hetil. 2021; 162(33): 1311-1317. Summary. The treatment of chronic diseases, including inflammatory bowel disease, is a complex task that requires the collaboration of health professionals with up-to-date expertise and experience under the appropriate technical conditions. Our aim was to systematically review the management of inflammatory bowel disease. We focused on the issue of early diagnosis and referral to a specialist, the need for personalized therapy and "treat-to-target" concept, and the appropriate timing of referral to a biological therapy center. The levels of competent and responsible care and the structure of a multidisciplinary team were also discussed. For the article, international and Hungarian therapeutic protocols and literature were reviewed. The collaboration of disciplines is essential in the management of chronic diseases. For disease management, it is critical to be up-to-date with changing recommendations, protocols, and to adopt competency levels to achieve a patient's adequate quality of life and reduce disease complications. Orv Hetil. 2021; 162(33): 1311-1317
Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD)
Inflammatory bowel disease does not alter the clinical features and the management of acute pancreatitis: A prospective, multicentre, exact-matched cohort analysis
Objective and aims: Acute pancreatitis in inflammatory bowel disease occurs mainly
as an extraintestinal manifestation or a side effect of medications. We aimed to
investigate the prognostic factors and severity indicators of acute pancreatitis and the
treatment of patients with both diseases.
Design: We performed a matched case-control registry analysis of a multicentre,
prospective, international acute pancreatitis registry. Patients with both diseases were
matched to patients with acute pancreatitis only in a 1:3 ratio by age and gender.
Subgroup analyses were also carried out based on disease type, activity, and
treatment of inflammatory bowel disease.
Results: No difference in prognostic factors (laboratory parameters, bedside index of
severity in acute pancreatitis, imaging results) and outcomes of acute pancreatitis
(length of hospitalization, severity, and local or systemic complications ) were
detected between groups. Significantly lower analgesic use was observed in the
inflammatory bowel disease population. Antibiotic use during acute pancreatitis was
significantly more common in the immunosuppressed group than in the nonimmunosuppressed group (p=0.017). However, none of the prognostic parameters or
the severity indicators showed a significant difference between any subgroup of
patients with inflammatory bowel disease.
Conclusion: No significant differences in the prognosis and severity of acute
pancreatitis could be detected between patients with both diseases and with
pancreatitis only. The need for different acute pancreatitis management is not justified
in the coexistence of inflammatory bowel disease, and antibiotic overuse should be
avoide
Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients
Background: Patients with inflammatory bowel disease (IBD) have a high risk for infection. Pneumonia
related to influenza and pneumococcal infection is one of the most common infection-related complications
in IBD.
Aims: To evaluate the immunogenicity of pneumococcal and influenza vaccination in patients with IBD
receiving different treatments.
Methods: We searched four databases for studies evaluating seroprotection and seroconversion rates
after influenza or pneumococcal vaccination in IBD on 20th October 2020. In the meta-analysis, odds
ratios (OR) were calculated with 95% confidence intervals (CI).
Results: We included twelve studies (1429 patients with IBD) in this meta-analysis. The seroconversion
rate after pneumococcal vaccination and the seroprotection rate after influenza vaccination were not significantly
lower in patients receiving conventional immunosuppressive treatment compared to the nonimmunosuppressed
patients. Meanwhile, the seroconversion rate following pneumococcal vaccine was
significantly lower in patients with anti-TNF mono- or combination therapy (OR = 0.28, CI: 0.15–0.53,
and OR = 0.27, CI: 0.15–0.49, respectively). In the analysis of patients with IBD on conventional immunosuppressive
monotherapy versus anti-TNF therapy, the seroprotection rate after influenza immunization
did not differ between patients receiving either anti-TNF mono-or combination therapy (OR = 1.45, CI:
0.62–3.38 and OR = 0.91, CI: 0.37–2.22, respectively).
Conclusion: Our data suggest that the immunization against Pneumococcus and influenza is safe and
immunogenic despite immunosuppression
Hungarian Linguistic, Cross-Cultural, and Age Adaptation of the Patient Satisfaction with Health Care in Inflammatory Bowel Disease Questionnaire (CACHE) and the Medication Adherence Report Scale (MARS)
Abstract: Background: The TRANS-IBD study examines the superiority of joint transition visits, with
drug adherence and patient satisfaction among the outcome measures. Our aim was a cross-cultural,
age- and disease-specific adaptation of the ‘Medication Adherence Rating Scale’ (MARS) and ‘Patient
satisfaction with health care in inflammatory bowel disease questionnaire’ (CACHE) questionnaires
in patients with inflammatory bowel disease (IBD). Methods: Linguistic and cultural adaptation
using test and re-test procedures were performed. Internal consistency with Cronbach’s α coefficients,
confirmatory factor analyses with root Mean Square Error of Approximation (RMSEA), Comparative
Fit Index (CFI), and Tucker-Lewis Index (TLI) were determined. Results: A total of 122 adolescents
and 164 adults completed the questionnaires (47.5% male, mean age 17 ± 1; and 29.3% male, mean
age 38 ± 11, respectively). In the MARS questionnaire, Cronbach’s α scores were found good in
adolescents (0.864) and acceptable in adults (0.790), while in the CACHE questionnaire, scores were
rated as excellent in both populations (0.906 and 0.945, respectively). The test-retest reliabilities were
satisfactory in both groups (MARS questionnaire: r = 0.814 and r = 0.780, CACHE questionnaire:
r = 0.892 and r = 0.898, respectively). RMSEA showed poor fit values in the MARS questionnaire and
reasonable fit values in the CAHCE questionnaire, CFI and TLI had statistically acceptable results.
Conclusion: Age-and disease-specific Hungarian versions of the questionnaires were developed,
which are appropriate tools for TRANS-IBD RCT and daily IBD car
Inflammatory bowel disease does not alter the clinical features and the management of acute pancreatitis: A prospective, multicentre, exact-matched cohort analysis
Acute pancreatitis in inflammatory bowel disease occurs mainly as an extraintestinal manifestation or a side effect of medications. We aimed to investigate the prognostic factors and severity indicators of acute pancreatitis and the treatment of patients with both diseases.We performed a matched case-control registry analysis of a multicentre, prospective, international acute pancreatitis registry. Patients with both diseases were matched to patients with acute pancreatitis only in a 1:3 ratio by age and gender. Subgroup analyses were also carried out based on disease type, activity, and treatment of inflammatory bowel disease.No difference in prognostic factors (laboratory parameters, bedside index of severity in acute pancreatitis, imaging results) and outcomes of acute pancreatitis (length of hospitalization, severity, and local or systemic complications) were detected between groups. Significantly lower analgesic use was observed in the inflammatory bowel disease population. Antibiotic use during acute pancreatitis was significantly more common in the immunosuppressed group than in the non-immunosuppressed group (p = 0.017). However, none of the prognostic parameters or the severity indicators showed a significant difference between any subgroup of patients with inflammatory bowel disease.No significant differences in the prognosis and severity of acute pancreatitis could be detected between patients with both diseases and with pancreatitis only. The need for different acute pancreatitis management is not justified in the coexistence of inflammatory bowel disease, and antibiotic overuse should be avoided
Hungarian Linguistic, Cross-Cultural and Age Adaptation of Transition Specific Questionnaires in Patients with Inflammatory Bowel Disease
Objective: In the TRANS–IBD clinical trial, the outcomes are measured with selected validated questionnaires. Cross-cultural and age adaptations of the Self-Efficacy Scale for adolescents and young adults (IBD–SES), the Transition Readiness Assessment Questionnaire (TRAQ), and the Self-Management and Transition Readiness Questionnaire (STARx) were performed. Methods: Linguistic and cultural adaptation was carried out with the usage of reliability coefficients (Cronbach’s α coefficients, Spearman’s rank correlation), and with confirmatory factor analysis (CFA; root Mean Square Error of Approximation [RMSEA], Comparative Fit Index [CFI], and Tucker-Lewis Index [TLI]). Results: 112 adolescents participated in the study (45.5% male, mean age 17 ± 1.98 years). CFA was acceptable in the IBD–SES and the TRAQ. Internal consistency was acceptable in IBD–SES and good in TRAQ (0.729; 0.865, respectively). Test–retest reliability was good in IBD–SES, but below the acceptable threshold in TRAQ (ρ = 0.819; ρ = 0.034). In STARx tools, RMSEA showed poor fit values, CFI and TLI were below acceptable fit values, and internal consistency was not satisfied (0.415; 0.693, respectively), while test–retest reliabilities were acceptable (ρ = 0.787; ρ = 0.788, respectively). Conclusions: Cross-cultural, age-specific adaptation was successfully completed with IBD–SES and TRAQ. Those are comparable to the original validated versions. The adaption of the STARx tools was not successful
Inflammatory bowel disease does not alter the clinical features and the management of acute pancreatitis: A prospective, multicentre, exact-matched cohort analysis
Acute pancreatitis in inflammatory bowel disease occurs mainly as an extraintestinal manifestation or a side effect of medications. We aimed to investigate the prognostic factors and severity indicators of acute pancreatitis and the treatment of patients with both diseases.We performed a matched case-control registry analysis of a multicentre, prospective, international acute pancreatitis registry. Patients with both diseases were matched to patients with acute pancreatitis only in a 1:3 ratio by age and gender. Subgroup analyses were also carried out based on disease type, activity, and treatment of inflammatory bowel disease.No difference in prognostic factors (laboratory parameters, bedside index of severity in acute pancreatitis, imaging results) and outcomes of acute pancreatitis (length of hospitalization, severity, and local or systemic complications) were detected between groups. Significantly lower analgesic use was observed in the inflammatory bowel disease population. Antibiotic use during acute pancreatitis was significantly more common in the immunosuppressed group than in the non-immunosuppressed group (p = 0.017). However, none of the prognostic parameters or the severity indicators showed a significant difference between any subgroup of patients with inflammatory bowel disease.No significant differences in the prognosis and severity of acute pancreatitis could be detected between patients with both diseases and with pancreatitis only. The need for different acute pancreatitis management is not justified in the coexistence of inflammatory bowel disease, and antibiotic overuse should be avoided